Mounjaro launches with an oral contraceptive warning no semaglutide product carries
Mounjaro's FDA label tells people on birth control pills to add a barrier method or switch to a non-oral method for four weeks after starting and after each dose increase — an instruction tied to how tirzepatide slows stomach emptying.
When tirzepatide launched in the United States as Mounjaro in 2022, its FDA-approved labeling included a contraception instruction that has followed the drug ever since: people using oral contraceptives should switch to a non-oral method, or add a barrier method, for four weeks after starting the drug and for four weeks after each dose increase [1].
The instruction sits in Section 8.3 of the prescribing information, "Females of Reproductive Potential," and it is summarized in the label's Highlights section, the one-page overview prescribers read first [1]. It is still there in the version of the label posted on DailyMed with a revision date of August 2026 [1].
What the label says and why
The reasoning is in the drug interactions section. Mounjaro "delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications," according to Section 7.2 [1]. Birth control pills have to be absorbed from the gut to work, so a slowdown in how fast the stomach empties can matter most in the windows when the body is adjusting to a new dose.
Those windows are frequent early on. Mounjaro starts at 2.5 mg injected under the skin once weekly, and the dose can be raised in 2.5 mg steps after at least four weeks on the current dose, up to a maximum of 15 mg weekly in adults and 10 mg weekly in pediatric patients 10 years and older [1]. Someone who climbs from the 2.5 mg starting dose to the 15 mg maximum passes through five increases. Because the label attaches a four-week backup-contraception period to the start and to each escalation, that stretch of titration can be covered almost continuously [1].
Mounjaro is a GIP and GLP-1 receptor agonist approved as an adjunct to diet and exercise for type 2 diabetes in adults and children 10 and older, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk [1]. Its initial U.S. approval was in 2022 [1].
One caution about the comparison in the headline: the sources available here include only the tirzepatide label [1] and the title of a Journal of the American Pharmacists Association paper, "The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception" [2]. The semaglutide prescribing information for Ozempic, Wegovy and Rybelsus is not among these sources, so the claim that no semaglutide product carries this instruction cannot be verified from the documents provided. What can be verified is that tirzepatide's label carries it [1].
Why it matters for patients
Practically, this is a labeled instruction that many people never hear about, because it lives in a section of the prescribing information that does not always come up in a short appointment. It applies to pills, not to the drug's other warnings, and it is time-limited — four weeks after starting, four weeks after each step up [1].
It also intersects with another part of the label. Mounjaro's pregnancy section says that, based on animal studies, the drug may cause fetal harm [1]. So the contraception instruction is not a minor administrative note; it connects to a stated pregnancy risk.
For people comparing tirzepatide with semaglutide, the contraception language is one concrete, written difference to ask a prescriber or pharmacist about, rather than something to infer from marketing or online discussion. Questions about which contraceptive methods count as "non-oral" or "barrier" are clinical ones for a healthcare professional.
What happens next
The Mounjaro label continues to change. DailyMed lists recent major changes including a pediatric indication in December 2025, a major adverse cardiovascular events indication and revised recommended dosage in August 2026, updated administration instructions in January 2026, and a new warning about never sharing a KwikPen between patients in January 2026 [1]. The contraception instruction is not listed among those recent changes, meaning it has carried forward unchanged [1]. Whether future labeling revisions alter it is not known from these sources.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.